Figure 2
Validation in (a) the MDA cohort and (b) the TCGA cohort confirmed the poor prognosis of a similar proportion of patients (a: 12,3% and b: 12,6%) with the highest CDKN2A expression. (n.d. = not defined).
Figure 2 | Scientific Reports
Validation in (a) the MDA cohort and (b) the TCGA cohort confirmed the poor prognosis of a similar proportion of patients (a: 12,3% and b: 12,6%) with the highest CDKN2A expression. (n.d. = not defined).
